Next Day DeliveryRegistered Pharmacy100% OnlineFully Inspected & Regulated ServicesApproved UK-licensed TreatmentsNext Day DeliveryRegistered Pharmacy100% OnlineFully Inspected & Regulated ServicesApproved UK-licensed Treatments
10 May 2026
8min read
Contents
Author
.png&w=1440&q=75)
Important: Wegovy is a prescription-only medicine. The decision to prescribe is made by an independent UK-registered prescriber after a clinical assessment.
Wegovy 7.2mg is the higher weekly semaglutide maintenance dose approved in the UK for adults with obesity. The MHRA first approved the 7.2mg maximum weekly dose on 6 January 2026. At that point, patients needed to use three 2.4mg doses on the same day. On 14 April 2026, the MHRA approved a single-dose 7.2mg Wegovy pen, making the higher dose simpler to administer.
This dose is not a shortcut or a starting dose. It is designed for selected patients who have already worked through the standard Wegovy titration ladder, usually reached 2.4mg, tolerated semaglutide well, and need further clinical support after a plateau. At LYV, escalation should happen only after pharmacist-led review, not automatically.
A higher weekly semaglutide maintenance dose approved for adults with obesity.
The MHRA approved Wegovy doses up to 7.2mg per week on 6 January 2026.
On 14 April 2026, the MHRA approved a dedicated single-dose Wegovy 7.2mg pen.
Before the single-dose pen became available, patients required three 2.4mg injections on the same day to reach a 7.2mg dose.
No. Wegovy 7.2mg is not a starter dose and should only be used after completing the recommended dose-escalation schedule.
Evidence comes primarily from the STEP UP clinical trial programme involving patients already established on semaglutide treatment.
The higher maintenance dose provides an additional treatment option for selected patients who require further weight-loss support under clinical supervision.
Until 2026, the familiar Wegovy weight-management pathway in the UK built up to a 2.4mg once-weekly maintenance dose. That remains a major maintenance dose for many patients, and many people should stay there if they are still losing weight steadily or tolerating treatment only just well enough.
The 2026 change created a new option above 2.4mg. The January authorisation mattered because it gave clinicians a route for selected patients who had plateaued on the previous maximum. The April single-dose pen approval mattered because it made the dose easier to administer and removed the earlier need to take three 2.4mg doses together.
For SEO and patient clarity, these two dates should be kept separate on the page: January 2026 was the dose approval; April 2026 was the single-dose pen approval.
Wegovy 7.2mg is a weekly dose. Since the April 2026 approval of the single-dose pen, eligible patients may be prescribed the 7.2mg pen where clinically appropriate and available. Before that pen was approved, the authorised method required three 2.4mg injections on the same day. Older content that says there is no single 7.2mg pen should now be updated.
Patients should not try to create this dose themselves, combine pens without clinical instruction, or accelerate their dose ladder because weight loss has slowed. A higher dose can increase side effects and should be considered only after a prescriber reviews weight-loss response, tolerability, BMI, relevant conditions, current medicines and safety history.
The STEP UP trial programme is the key evidence base behind the higher dose. In plain English, the question was whether patients already established on semaglutide could gain additional benefit by escalating beyond 2.4mg.
The headline is useful but should not be oversold: higher-dose Wegovy can provide further weight-loss support for selected patients, especially where progress has stalled on 2.4mg. However, it is not the right answer for every plateau, and it is not a substitute for reviewing diet, side effects, adherence, activity, sleep, alcohol intake and other medication.
A patient may be a better candidate for a Wegovy 7.2mg review if they:
This is the credibility section. A good pharmacy page should be willing to say when a dose is not suitable.
The side effects are broadly the same as other semaglutide doses, but they may be more common or more noticeable after escalation. The most expected side effects are nausea, constipation, diarrhoea, indigestion, bloating, reduced appetite and occasional vomiting.
Most manageable side effects appear during the first few weeks after a dose change. Patients usually do best when they reduce portion size, eat slowly, avoid very fatty meals, maintain hydration and contact the pharmacy early if symptoms are not settling.
Many patients searching for Wegovy 7.2mg are also comparing it with Mounjaro. This is sensible: both sit in the higher-intensity end of private weight-management treatment, but they are not the same medicine.
The right decision is not only about headline average weight loss. A prescriber should also consider tolerability, previous response, side-effect history, price, availability, contraindications and patient preference. For a patient doing well on semaglutide apart from a plateau, escalation may feel lower-friction than switching. For a patient with poor semaglutide tolerance or limited response, a different treatment discussion may be more appropriate.
This section should convert without sounding pushy. The LYV advantage is not automatic dose escalation; it is supervised, pharmacist-led decision-making.
This article is general information for UK adults and is not a substitute for personalised medical advice. Prescription-only medicines mentioned are supplied only after a clinician-led consultation through a regulated pharmacy. If you have urgent symptoms or concerns about a medicine, speak to your GP, pharmacist, NHS 111 or emergency services as appropriate.
